GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » Price-to-Free-Cash-Flow

Immunome (Immunome) Price-to-Free-Cash-Flow : 42.82 (As of May. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immunome Price-to-Free-Cash-Flow?

As of today (2024-05-12), Immunome's share price is $15.50. Immunome's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.36. Hence, Immunome's Price-to-Free-Cash-Flow Ratio for today is 42.82.

The historical rank and industry rank for Immunome's Price-to-Free-Cash-Flow or its related term are showing as below:

IMNM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 20.73   Med: 41.29   Max: 73.54
Current: 42.82

During the past 6 years, Immunome's highest Price-to-Free-Cash-Flow Ratio was 73.54. The lowest was 20.73. And the median was 41.29.

IMNM's Price-to-Free-Cash-Flow is ranked worse than
58.18% of 220 companies
in the Biotechnology industry
Industry Median: 31.585 vs IMNM: 42.82

Immunome's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.41. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.36.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 51.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 18.00% per year.

During the past 6 years, Immunome's highest 3-Year average Free Cash Flow per Share Growth Rate was 51.70% per year. The lowest was -11.70% per year. And the median was 3.00% per year.


Immunome Price-to-Free-Cash-Flow Historical Data

The historical data trend for Immunome's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunome Price-to-Free-Cash-Flow Chart

Immunome Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Immunome Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 43.02 26.19 38.48 -

Competitive Comparison of Immunome's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Immunome's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunome's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Immunome's Price-to-Free-Cash-Flow falls into.



Immunome Price-to-Free-Cash-Flow Calculation

Immunome's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=15.50/0.362
=42.82

Immunome's Share Price of today is $15.50.
Immunome's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Immunome  (NAS:IMNM) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Immunome Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Immunome's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunome (Immunome) Business Description

Traded in Other Exchanges
N/A
Address
665 Stockton Drive, Suite 300, Exton, PA, USA, 19341
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. It primarily operates in the U.S. Its current programs comprise Oncology (IMM-ONC-01), SARS-CoV-2 (IMM-BCP-01), and IMM20059 Anti-EPN1.
Executives
Jean Jacques Bienaime director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Robert Lechleider officer: Chief Medical Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett officer: SVP Operations C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Jack Higgins officer: Chief Scientific Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas director, other: See remarks 1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner officer: Chief Strategy Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson officer: Chief Technology Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp director, 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast director
Michael Lefenfeld director IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma director, officer: President and CEO IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim director 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019